Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache

This article was originally published here

Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA

The post Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply